𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗔𝗱𝗲𝗻𝗼𝘃𝗶𝗿𝗮𝗹 𝘃𝗲𝗰𝘁𝗼𝗿𝘀 𝗳𝗼𝗿 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆! In recent years, the world of drug development has soared to unprecedented heights, leveraging cutting-edge systems to enhance existing therapies and introduce groundbreaking treatment approaches. Among these advancements, gene therapy has emerged as a game-changer, bringing about an epochal shift in patient care. ❤️ Gene therapy holds the potential to stimulate cardiac angiogenesis and improve overall heart function, offering new hope to individuals with cardiovascular conditions. 🧬Promising human trials have shown success in enhancing cardiac angiogenesis and function using first-generation HAd-5 vectors. 🏭 Advancements in gene therapy product manufacturing and regulatory guidance have created a robust framework for gene therapy medicinal products (GTMPs). ✔️ If you're curious about the potential of gene therapy in treating cardiovascular diseases and its scalability, dive deeper into the topic here: https://lnkd.in/d-Dfqaeh We are proud to share that the co-authors of the paper are our CEO, Menzo Havenga, and our dedicated Director of Science and Innovation Wilfried Bakker. #GeneTherapy #ViralVector #Bataviabiosciences #Innovation #adenovirus #HealthcareRevolution #CardiovascularGeneTherapy #ViralVectors #ResearchBreakthroughs #GTMP #biotechnology
Over ons
Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies. We are not your standard CDMO - our customers regularly refer to us as their product development partner and thought partner. We focus on the early stages of product development with services ranging from DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization to clinical manufacturing. Headquartered in Leiden, The Netherlands, Batavia Biosciences is privileged to have strong strategic partners in both the EU and US. Batavia Biosciences aims to significantly contribute to ease human suffering from infectious disease and cancer.
- Website
-
https://www.bataviabiosciences.com
Externe link voor Batavia Biosciences
- Branche
- Biotechnologie
- Bedrijfsgrootte
- 201 - 500 medewerkers
- Hoofdkantoor
- Leiden
- Type
- Particuliere onderneming
- Opgericht
- 2010
- Specialismen
- Bioprocess Development, Virus & Cell Banking, Cell Line Generation, Clinical Manufacturing, Product Characterization, Project Management, Stable & Transient Protein Production, USP / DSP Optimization, Assay Development, Research Candidate Selection, Viral Vectors, Viral Vaccines Manufacturing en Viral Vectors Development
Locaties
-
Primair
Zernikedreef 16
Leiden, 2333 CL, NL
-
300 TradeCenter, Suite 6650
Woburn MA01801, USA, NL
Medewerkers van Batavia Biosciences
Updates
-
Dive into the intricate world of viral vector manufacturing and discover how Batavia Biosciences is overcoming industry challenges to revolutionize gene therapy and immuno-oncology! 🧬🔬 In this blog, the viral vector manufacturing expert Kai Touw, delves into the obstacles of viral vector production and unveils the innovative solutions we have implemented. Why Viral Vectors Matter: 🧬 𝗩𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿𝘀 are essential for delivering genetic material to cells, a critical step in developing therapies for genetic disorders and cancer. However, producing these vectors, particularly adeno-associated virus (AAV) and lentivirus-derived vectors, presents significant challenges Learn about: 🔬 𝗞𝗲𝘆 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 : Understand the major hurdles in producing adeno-associated virus (AAV) and lentivirus-derived vectors, including increasing viral vector titer, improving purification recovery, and enhancing product quality. 🔬𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 : Learn about our use of automation, process analytical tools, and stable vector producer cell lines to achieve higher titers and consistent quality. 🔬𝗛𝗜𝗣-𝗩𝗮𝘅® 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 : Discover how our scalable, fixed-bed bioreactor system boosts productivity, lowers costs, and solves capacity constraints with a smaller facility footprint. As pioneers in the biotech landscape, we're optimizing viral vector production to drive breakthroughs in gene therapy, vaccines, and beyond. Join us on this journey towards medical revolution and explore the full article here: 📖 https://lnkd.in/eW4Frxrk We're excited to start conversations and address any questions or challenges you might face in this dynamic field. 🤝 #GeneTherapy #ImmunoOncology #ATMPs #ViralVectors #Biotechnology #Innovation #Biopharma #BataviaBiosciences #HIPVax #Biomanufacturing
-
🎉🙌 Exciting News: Meet Our New Team Members! 🙌🎉 We are delighted to welcome the newest talents to our Batavia Team. A big round of applause for Odom, Roosmarijn and Albert! 👏 Their impressive skills and diverse backgrounds are a perfect fit for our mission of advancing biotechnology and delivering top-notch CDMO services, all in pursuit of reducing human suffering from diseases globally. 🌐 With their passion and commitment, we're even more equipped to make biopharmaceuticals more accessible and affordable worldwide. 🌿💼 #Team #CDMO #Biotech #CenterOfExcellence #NewTeamMembers #WelcomePost
-
Are you excited to dive deeper into Viral Vector Manufacturing? Eager to discover the intricate science behind groundbreaking innovations in gene therapy, vaccines, and beyond? 🧬🔬 Then this article is for you! In the article, we'll explore the entire process and share insights on how we work at Batavia, including a detailed look into preclinical and clinical manufacturing processes, and the importance of stringent regulatory compliance and product release. We're looking forward to starting conversations and answering any questions or challenges you might face. 🤝 #GeneTherapy #Vaccines #viralvaccine #CDMO #viralvectorsdevelopment #viralvectorsmanufacturing #vaccinemanufacturing #celltherapy #HealthcareInnovation #RegulatorySupport #ProductRelease https://lnkd.in/esJUjqTV
Viral Vector Manufacturing
bataviabiosciences.com
-
We asked ChatGPT what the difference is between producing viral vectors in-house or with the help of a CDMO.🧬 Here are its answers: 🔹 𝗜𝗻-𝗛𝗼𝘂𝘀𝗲 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻: Best for companies seeking full control, customization, and confidentiality in their viral vector production process. Ideal for those with resources for upfront investment. 🔹 𝗖𝗗𝗠𝗢: Ideal for companies seeking specialized expertise, rapid production timelines, and scalability without the need for heavy upfront investments. Perfect for those prioritizing speed to market and flexibility in production volumes . ChatGPT has its answers, and you? Which fits your viral vector production needs? If you’re still in doubt, let’s have a quick chat to talk about it. 👉 Book a call with a BD representative: https://lnkd.in/dU9y78fK #ViralVectors #Biotech #InHouseProduction #CDMO #Biomanufacturing #Pharma #Biotechnology #ProductionStrategy
-
Dive into the fascinating world of process development for viral vectors. Explore how we optimize and scale production, enabling high-quality vectors for gene therapy, vaccines, and beyond. Become part of the journey towards medical revolution. Learn about: - Guiding Principles 💪🏻 - Upstream Processing ⏫ - Downstream Processing ⏬ - Analytical Development 🧪 - In Silico Modeling 🖥 As pioneers in the biotech landscape, we are consistently optimizing the process of viral vector production to propel breakthroughs in gene therapy, vaccines, and beyond. https://lnkd.in/eTfHp3sk #viralvectors #drugdevelopment #cdmo #gentherapy #highquality
Process Development Viral Vectors
bataviabiosciences.com
-
𝗝𝗼𝗶𝗻 𝗕𝗮𝘁𝗮𝘃𝗶𝗮 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝘁 𝘁𝗵𝗲 𝟮𝟬𝟮𝟰 𝗡𝗜𝗜𝗠𝗕𝗟 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴! We are thrilled to announce that Batavia Biosciences will be present at the 2024 NIIMBL National Meeting, taking place from June 25-27, 2024, in Washington, D.C. and virtually. Save the date and join us for this prestigious event! Our Managing Director, Peter Abbink, Ph.D. , will be present with a scientific poster titled "Intensified Vaccine and Viral Vector Manufacturing Using the HIP-Vax® Platform" . This poster will highlight our innovative approaches and significant contributions to the biopharmaceutical manufacturing. 🧬 Event Details: 📅 June 25-27, 2024 🏢 Capital Hilton, Washington, D.C. / 💻 Virtual The NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals National Meeting is a unique opportunity to connect with esteemed colleagues and thought leaders in biopharmaceutical manufacturing. This event is exclusive to NIIMBL members and federal stakeholders, providing a platform to explore critical topics in our industry. About the poster: 🧬 💉 The poster will delve into the details of our HIP-Vax® platform, showcasing how it revolutionizes viral vaccine and viral vector manufacturing. Learn how our intensified processes increase yield, enhance product quality, and reduce costs. Our focus on scalable solutions addresses the current capacity constraints in the industry, making superior quality viral vectors more accessible for gene therapy and vaccine development. 🧬 💉 We look forward to sharing our expertise and connecting with you at the 2024 NIIMBL National Meeting. See you there! #NIIMBL2024 #Biopharmaceuticals #CDMO #Innovation #Biotech #Biomanufacturing #BataviaBiosciences #HIPVax #ViralVectors #GeneTherapy #PeterAbbink #Networking #Conference #ScientificResearch
-
🧬 𝗩𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿 𝗦𝗵𝗼𝗿𝘁𝗮𝗴𝗲 𝗣𝘂𝘁𝘀 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝘁 𝗥𝗶𝘀𝗸🧬 Have you considered how the current viral vector shortage could impact the future of gene therapy? 📊💡 Our latest LinkedIn carousel dives into this critical issue from a commercial perspective, highlighting 3 Pitfalls in the Production of Viral Vectors. Inside This Carousel: 1️⃣ An overview of Capex, Opex, and COGS and their roles in viral vector production. 2️⃣ How these financial factors contribute to the current shortage. 3️⃣ Why outsourcing to Contract Development and Manufacturing Organizations (CDMOs) is a strategic solution. Key Insights: 💡 Capex (Capital Expenditures): Significant investments in long-term assets are crucial but can be prohibitive. 💡 Opex (Operational Expenditures): Managing day-to-day operational costs while maintaining efficiency. 💡 COGS (Cost of Goods Sold): Understanding the direct costs of production and their impact on profitability and supply. 💡 Discover how strategic partnerships with CDMOs can help mitigate these challenges, streamline production, and ensure a stable supply of viral vectors, ultimately safeguarding the progression of gene therapy. Join us in exploring practical solutions to navigate and overcome the viral vector shortage. Together, we can drive the biotech industry forward and ensure the continued advancement of life-saving gene therapies. 👉 Connect with us to see how a CDMO partnership can help you avoid these pitfalls and ensure reliable viral vector development & production. https://lnkd.in/eB5_KDbT #Biotech #GeneTherapy #ViralVectors #Capex #Opex #COGS #CDMO #Sustainability #Innovation #Pharmaceuticals #Biomanufacturing
-
Want to Know More About Batavia Biosciences? Don’t Miss This Article! 🚀 𝗖𝗗𝗠𝗢𝘀: 𝗧𝗵𝗲 𝗧𝗼𝗼𝗹 𝗧𝗵𝗮𝘁 𝗧𝘂𝗿𝗻𝘀 𝗮 𝗛𝗼𝗽𝗲 𝗜𝗻𝘁𝗼 𝗮 𝗖𝘂𝗿𝗲 🧬 We're excited to share an insightful article authored by Peter Abbink, Ph.D. , the Managing Director of Batavia Biosciences Inc 🇺🇸 . This piece explores the role of Contract Development and Manufacturing Organizations (CDMOs) like Batavia Biosciences in transforming groundbreaking research into real-world therapies. Key Highlights: 🔬 Small labs often struggle with scaling up production for rare and orphan diseases. 🔬 CDMOs provide the necessary infrastructure, expertise, and regulatory compliance. 🔬 Batavia Biosciences has been a trusted partner for 14 years, aiding in the development of 𝘃𝗶𝗿𝗮𝗹 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀, 𝘃𝗲𝗰𝘁𝗼𝗿𝘀, 𝗽𝗿𝗼𝘁𝗲𝗶𝗻𝘀, 𝗮𝗻𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀. 🔬 The collaboration with Phoenix Nest Inc. showcases Batavia's impact on rare disease therapeutics, particularly for Sanfilippo syndrome Type D. Batavia’s Expansion: 🌍 A new commercial manufacturing facility in Leiden, the Netherlands, set to open in 2025. 🌍 The strategic partnership with South Korea’s CJ CheilJedang has fueled significant growth and innovation. 🔗 Read more about how CDMOs like Batavia Biosciences are bridging the gap between discovery and clinical application, ensuring that life-saving treatments reach those in need. https://lnkd.in/eH4M5rcE #Biotech #Pharmaceuticals #HealthcareInnovation #CDMO #BataviaBiosciences #RareDiseases #Celltherapy #GeneTherapy #DrugDevelopment #viralvector #viralvaccine #vaccinedevelopment
CDMOs: The Tool That Turns A Hope Into A Cure
ibtimes.com
-
Are you attending #BIO 2024 in San Diego? Then don't miss the opportunity to meet us. A team of our specialists will be there to answer all your questions on how to empower your viral vector development and manufacturing. We are specialists in: 🔸Improve product yield 🔸Reduce process development time 🔸Increase product stability See you there! ☀️ #viralvector #viralvaccine #cdmo #manufacturing #celltherapy #genetherapy #antibody Ron van Eijsden Carola Jüstel, MScJeffrey Kovacs, PhD Wendy Laird Peter Abbink, Ph.D.